Phibro Animal Health (NASDAQ:PAHC) Rating Lowered to “Hold” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other research firms have also recently issued reports on PAHC. Morgan Stanley increased their target price on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Barclays raised their price objective on Phibro Animal Health from $20.00 to $22.00 and gave the company an “underweight” rating in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating and three have given a hold rating to the company’s stock. According to MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and an average price target of $21.00.

Phibro Animal Health Price Performance

PAHC stock opened at $23.64 on Friday. The stock has a 50-day moving average price of $22.47 and a two-hundred day moving average price of $22.51. The stock has a market cap of $957.49 million, a PE ratio of 49.25, a price-to-earnings-growth ratio of 0.45 and a beta of 0.58. The company has a current ratio of 3.20, a quick ratio of 1.37 and a debt-to-equity ratio of 2.99. Phibro Animal Health has a 1 year low of $11.98 and a 1 year high of $26.55.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. Equities analysts forecast that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Phibro Animal Health in the 4th quarter valued at about $29,000. Lazard Asset Management LLC lifted its stake in Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company’s stock valued at $34,000 after purchasing an additional 1,589 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Phibro Animal Health in the 3rd quarter valued at about $70,000. Virtus Fund Advisers LLC acquired a new stake in Phibro Animal Health in the 4th quarter valued at about $69,000. Finally, Aquatic Capital Management LLC acquired a new stake in Phibro Animal Health in the 4th quarter valued at about $69,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.